DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Story continues below

On January 14, 2018, DENTSPLY SIRONA Inc. (the “Company”) appointed Donald M. Casey Jr. as the Chief Executive Officer of the Company and as a member of the Company’s Board of Directors, in each case effective February 12, 2018. Effective as of that date, Mr. Casey will succeed Mark A. Thierer, who has served as Interim Chief Executive Officer since September 28, 2017.

Mr. Casey, age 58, is currently the Chief Executive Officer of the Medical segment of Cardinal Health, Inc., a position he has held since 2012. From 2010 to 2012, Mr. Casey served as Chief Executive Officer of the Gary and Mary West Wireless Health Institute, a non-profit research organization focused on lowering the cost of health care through novel technology solutions. Prior to that, Mr. Casey held various positions with Johnson & Johnson. Mr. Casey has been a director of West Corporation since 2015.

The Company has entered into an employment agreement with Mr. Casey to which he will serve as Chief Executive Officer of the Company and, at any time during which the office of President of the Company is vacant, as its President. The employment agreement has a term of three years, which will renew for successive two-year periods absent 90 days’ notice by either party. Mr. Casey will be paid an annual base salary of $925,000, be eligible for a target annual bonus of 120% of base salary (on a pro-rated basis for 2018), be eligible for annual long-term incentive compensation with a grant date fair value of $4 million, receive a starting equity grant (weighted equally between stock options and performance stock units) with a grant date fair value of $1 million generally vesting after three years subject to continued employment, and receive two awards intended to compensate him for incentive compensation he will forfeit by reason of leaving his current employer, a $500,000 cash payment that is repayable if he voluntarily terminates his employment within one year and a restricted stock unit award with a grant date fair value of $4.2 million generally vesting subject to continued employment over three years at the rate 25%, 25% and 50% per annum, respectively.

If Mr. Casey’s employment is terminated by the Company without cause or by Mr. Casey for good reason, then (subject to execution of a release of claims if the termination occurs before a change in control of the Company), he would be paid an amount equal to two times the sum of his salary and target bonus over two years (in a lump sum if the termination occurs following a change in control), a pro-rata actual annual bonus, and an amount equal to two years of continued medical and retirement benefits, he would be eligible for two years of certain welfare benefit continuation subject to his paying the applicable employee premium cost and (if the termination occurs before a change in control) eighteen months of outplacement assistance, and, subject to different treatment that may be applicable upon a change in control, he would be credited with an additional two years of service for equity award vesting purposes.

The agreement also subjects Mr. Casey to certain confidentiality obligations and two-year noncompetition/nonsolicitation restrictions.

The foregoing summary of Mr. Casey’s employment agreement is qualified in its entirety by reference to the text of the agreement, which is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Item 8.01 Other Events.

On January 17, 2018, the Company issued a press release announcing the appointment of Mr. Casey. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.


DENTSPLY SIRONA Inc. Exhibit
EX-10.1 2 ex10-1.htm EXHIBIT 10.1 – EMPLOYMENT AGREEMENT   Exhibit 10.1   EXECUTION VERSION Employment Agreement This Employment Agreement (this “Agreement”),…
To view the full exhibit click here

About DENTSPLY SIRONA Inc. (NASDAQ:XRAY)

DENTSPLY SIRONA Inc., formerly DENTSPLY International Inc., designs, develops, manufactures and markets a range of consumable dental products for the professional dental market. The Company also manufactures and markets consumable medical device products consisting mainly of urological catheters and certain surgical products. The Company’s segments include Dental Consumables, Endodontic and Dental Laboratory Businesses; Healthcare, Orthodontic and Implant Businesses, and Select Developed and Emerging Markets Businesses. The Company’s principal product categories are dental consumable products, dental laboratory products, dental specialty products and consumable medical device products. The Company distributes its products in over 120 countries. It offers brands, such as ANKYLOS, AQUASIL ULTRA, ARTICADENT, XIVE, ORAQIX, XYLOCAINE, ZHERMACK, IN-OVATION, LOFRIC, MAILLEFER, MIDWEST, NUPRO, ORIGO, OSSEOSPEED and PALODENT PLUS.

An ad to help with our costs